Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NCF1 | P14598 | 4/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 8/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273255 | 0.76 | MAPT (0.53) | MAPTNCF1SCN9AHRH3PDE3B | |
| SCHEMBL21273252 | 0.76 | MAPT (0.53) | MAPTNCF1SCN9AHRH3PDE3B | |
| SCHEMBL19066016 | 0.73 | MAPT (0.58) | MAPTNCF1APP | |
| SCHEMBL10458381 | 0.72 | CA12 (0.59) | MAPTNCF1APPHDAC1 | |
| SCHEMBL2157879 | 0.71 | HDAC1 (0.42) | HRH3PDE3BPDE3AHDAC1 | |
| SCHEMBL7835292 | 0.71 | MAPT (0.56) | MAPTNCF1APP | |
| SCHEMBL10458239 | 0.69 | CA12 (0.56) | MAPTAPPHDAC1 | |
| SCHEMBL1460148 | 0.67 | HDAC8 (0.62) | MAPTNCF1HDAC1 | |
| SCHEMBL9985738 | 0.67 | CA12 (0.50) | MAPT | |
| SCHEMBL21282212 | 0.67 | MAPT (0.46) | MAPTNCF1PDE3BPDE3AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012394-B2 | Alpha-synuclein ligands | WASHINGTON UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| US-20190256492-A1 | ALPHA-SYNUCLEIN LIGANDS | WASHINGTON UNIVERSITY (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256492-A1 | ALPHA-SYNUCLEIN LIGANDS | SNCA, PARK7, LRRK2 | MAPT 58/4885NCF1 1403/4885SCN9A 2964/4885 |
| US-12012394-B2 | Alpha-synuclein ligands | SNCA, PARK7, LRRK2 | MAPT 58/4885NCF1 1403/4885SCN9A 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.